159634-63-6

Basic information

• Product Name: Spiro[piperidine-4,4'(1'H)-quinolin]-2'(3'H)-one
• Synonyms: Spiro[piperidine-4,4'(1'H)-quinolin]-2'(3'H)-one;1'H-Spiro[Piperidine-4,4'-Quinolin]-2'(3'H)-One
• CAS NO: 159634-63-6
• Molecular Formula: C₁₃H₁₆N₂O
• Molecular Weight: 216.27894
• Mol File: 159634-63-6.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 427.9±45.0 °C(Predicted)
• Appearance: /
• Density: 1.20±0.1 g/cm3(Predicted)
• PKA: 14.67±0.20(Predicted)
• CAS DataBase Reference: Spiro[piperidine-4,4'(1'H)-quinolin]-2'(3'H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: Spiro[piperidine-4,4'(1'H)-quinolin]-2'(3'H)-one(159634-63-6)
• EPA Substance Registry System: Spiro[piperidine-4,4'(1'H)-quinolin]-2'(3'H)-one(159634-63-6)

Safety Data

• Hazardous Substances Data: 159634-63-6(Hazardous Substances Data)

Usage

General Description

Spiro[piperidine-4,4'(1'H)-quinolin]-2'(3'H)-one, also known as quinolone alkaloid, is a biologically active chemical compound derived from natural sources such as plants and microorganisms. It possesses a unique spirocyclic structure, with a piperidine and quinoline ring system. Spiro[piperidine-4,4'(1'H)-quinolin]-2'(3'H)-one has shown a wide range of pharmaceutical activities, including antibacterial, antifungal, antiviral, and antitumor properties. Its potential as a therapeutic agent in the treatment of various diseases, including cancer, infectious diseases, and neurological disorders, has been widely studied. The complex structure of spiro[piperidine-4,4'(1'H)-quinolin]-2'(3'H)-one makes it an interesting target for medicinal chemistry research and drug development.

Upstream product

• 159634-60-3 1'-(2,2,2-trifluoroacetyl)spiro[indene-1,4'-piperidin]-3(2H)-one 
• 159634-59-0 2,3-dihydro-3-oxo-spiro[1H-indene-1,4'-piperidine]-1'-carboxylic acid 1,1-dimethylethyl ester 
• 180465-55-8 spiro[1H-indene-1,4'-piperidin]-3(2H)-one 
• 878167-51-2 benzyl 2'-oxo-2',3'-dihydro-1'H-spiro[piperidine-4,4'-quinoline]-1-carboxylate 
• 159634-62-5 1-(2,2,2-trifluoroacetyl)-1'H-spiro[piperidine-4,4'-quinolin]-2'(3'H)-one 

Downstream Products

• 1032143-13-7 1'-(tert-butyloxycarbonyl)spiro(tetrahydroquinol-2-one)-4'-piperidine 
• 1032143-15-9 1'-(tert-butyloxycarbonyl)spiro(tetrahydroisoquinol-1-one)-4'-piperidine 
• 917898-66-9 1-neopentyl-1'-(2-nitrophenyl)-2',3'-dihydro-1'H-spiro[piperidine-4,4'-quinoline] 

Relevant articles and documents

Conformationally constrained ortho- Anilino diaryl ureas: Discovery of 1-(2-(1′-Neopentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl) -3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist

Preclinical antithrombotic efficacy and bleeding models have demonstrated that P2Y1 antagonists are efficacious as antiplatelet agents and may offer a safety advantage over P2Y12 antagonists in terms of reduced bleeding liabilities. In this article, we describe the structural modification of the tert-butyl phenoxy portion of lead compound 1 and the subsequent discovery of a novel series of conformationally constrained ortho-anilino diaryl ureas. In particular, spiropiperidine indoline-substituted diaryl ureas are described as potent, orally bioavailable small-molecule P2Y1 antagonists with improved activity in functional assays and improved oral bioavailability in rats. Homology modeling and rat PK/PD studies on benchmark compound 3l will also be presented. Compound 3l was our first P2Y1 antagonist to demonstrate a robust oral antithrombotic effect with mild bleeding liability in the rat thrombosis and hemostasis models.

MODULATORS OF MUSCARINIC RECEPTORS

The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

SPIRO-SUBSTITUTED AZACYCLES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is directed to spiro-substituted azacycles of the Formula 1: STR1 (wherein R 1, l, m, Q, W, X, Y, and Z are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.